These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30260533)

  • 1. An alternative method to analyse the biomarker-strategy design.
    Kunz CU; Jaki T; Stallard N
    Stat Med; 2018 Dec; 37(30):4636-4651. PubMed ID: 30260533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine.
    Dunn G; Emsley R; Liu H; Landau S
    Clin Trials; 2013 Oct; 10(5):709-19. PubMed ID: 24000376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
    Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
    BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothesis testing and estimation in ordinal data under a simple crossover design.
    Lui KJ; Chang KC
    J Biopharm Stat; 2012; 22(6):1137-47. PubMed ID: 23075013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the design and the analysis of stratified biomarker trials in the presence of measurement error.
    Halabi S; Lin CY; Liu A
    Stat Med; 2021 May; 40(12):2783-2799. PubMed ID: 33724513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample sizes for clinical trials using sputum eosinophils as a primary outcome.
    Dasgupta A; Zhang S; Thabane L; Nair P
    Eur Respir J; 2013 Oct; 42(4):1003-11. PubMed ID: 23349443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculations for randomised trials including both independent and paired data.
    Yelland LN; Sullivan TR; Price DJ; Lee KJ
    Stat Med; 2017 Apr; 36(8):1227-1239. PubMed ID: 28074483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On study designs and hypotheses for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Contemp Clin Trials; 2017 Nov; 62():140-145. PubMed ID: 28838813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjusting for misclassification in a stratified biomarker clinical trial.
    Liu C; Liu A; Hu J; Yuan V; Halabi S
    Stat Med; 2014 Aug; 33(18):3100-13. PubMed ID: 24733510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size and threshold estimation for clinical trials with predictive biomarkers.
    Mackey HM; Bengtsson T
    Contemp Clin Trials; 2013 Nov; 36(2):664-72. PubMed ID: 24064355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial.
    Li L; Ivanova A
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38861372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma Phenotypes and Endotypes: Implications for Personalised Therapy.
    Dean K; Niven R
    BioDrugs; 2017 Oct; 31(5):393-408. PubMed ID: 28879503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.